Evidence map›Paper›PMID 31588260›Full record

ReviewChemical science2019

Strategies based on metal-based nanoparticles for hypoxic-tumor radiotherapy.

Chenyang Zhang, Liang Yan, Zhanjun Gu, Yuliang Zhao

Open access · diamondAbstract readReview
In one paragraph

Review in Chemical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 144 citations in OpenAlex.

  1. State-of-the-art application of nanoparticles in radiotherapy: a platform for synergistic effects in cancer treatment.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Metal-based nanoparticle in cancer treatment: lessons learned and challenges.Frontiers in bioengineering and biotechnology · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Tween-20-Modified BiVOACS omega · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Pharmaceutics · 2022
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Chenyang ZhangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety , Institute of High Energy Physics , Chinese Academy of Sciences , Beijing 100049 , China . Email: zjgu@ihep.ac.cn.
Liang YanCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety , Institute of High Energy Physics , Chinese Academy of Sciences , Beijing 100049 , China . Email: zjgu@ihep.ac.cn.ORCID 0000-0003-2925-5544
Zhanjun GuCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety , Institute of High Energy Physics , Chinese Academy of Sciences , Beijing 100049 , China . Email: zjgu@ihep.ac.cn.ORCID 0000-0003-3717-2423
Yuliang ZhaoCAS Center for Excellence in Nanoscience , National Center for Nanoscience and Technology of China , Chinese Academy of Sciences , Beijing 100190 , China . Email: zhaoyl@nanoctr.cn.
Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy (RT) is one of the most effective and frequent clinical cancer treatments. Nevertheless, RT can cause damage to normal tissues around tumors under high-dose ionizing radiation. Inspired by versatile metal-based nanomaterials, great efforts have been devoted to developing nanomaterials with high-Z metal elements as radiosensitizers by depositing more energy into tumors for RT enhancement. However, these metal-based nanomaterial-mediated RTs are highly O

Identifiers

PMID31588260
PMCPMC6676466
OpenAlexW2950056753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.